Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-03-06

FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc, introducing the extended-release formulation a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XELJANZ XR (tofacitinib)

Snippet

SUPPL AP for XELJANZ XR (TOFACITINIB)